PortfoliosLab logoPortfoliosLab logo

HEAW.L's Sharpe Ratio of 1.17 indicates that for each unit of volatility, it generates 1.17 units of excess return above the risk-free rate. The ratio is calculated using historical daily returns over the past 12 months (as of Jul 16, 2026).

Sharpe uses total volatility (standard deviation) which includes both upside and downside price movements, making it useful for comparing risk-adjusted returns across different assets. For how to read this number and when it can mislead, see Sharpe Ratio Explained.

HEAW.L Sharpe Ratio Rank


HEAW.L Sharpe Ratio Rank: 38.939
Below Average

HEAW.L ranks above 38.9% of all investments in our database based on Sharpe Ratio over the past 12 months, indicating below-average returns relative to volatility. Securities are ranked from 0 (worst) to 100 (best).

What moves the rank

  • Strong returns with low total volatility → Higher rank
  • High volatility (both upside and downside) → Lower rank
  • Consistent returns → Higher rank than volatile returns of same magnitude
  • Sharp drawdowns increase volatility → Lower rank

What you can do with this information

  • Returns may not adequately compensate for volatility taken
  • Consider smaller allocation given below-average risk-adjusted profile
  • Explore higher-ranked investments with better consistency
  • Assess whether the volatility profile aligns with your portfolio goals

HEAW.L Sharpe Ratio Market Positioning

The chart shows HEAW.L's Sharpe Ratio relative to all ETFs on our platform, with color zones indicating percentile rankings. Higher ratios indicate better risk-adjusted returns.


  • Red zone (bottom 25%): 0.74 or lower
  • Yellow zone (middle 50%): 0.74 to 1.91
  • Green zone (top 25%): 1.91 or higher
  • Top 1%: 6.54+
  • Median: 1.42 — half of all investments score higher

How it compares to other similar ETFs

The table compares SPDR MSCI World Health Care UCITS ETF's Sharpe Ratio with other ETFs in the Health & Biotech Equities category across multiple time periods, showing how HEAW.L's risk-adjusted performance compares to similar funds.

Data shows 1-, 5-, and 10-year periods, plus each fund's all-time average, as of Jul 16, 2026.


SymbolName1Y Sharpe Ratio5Y Sharpe Ratio10Y Sharpe RatioAll Time Sharpe Ratio
BTEK.LiShares Nasdaq US Biotechnology UCITS ETF2.46
SBIO.LInvesco Nasdaq Biotech UCITS ETF2.43
BTEC.LiShares Nasdaq US Biotechnology UCITS ETF USD (Acc)2.42
BTEE.LiShares Nasdaq US Biotechnology UCITS ETF USD (Dist)2.41
FBT.LFirst Trust NYSE Arca Biotechnology UCITS ETF Acc2.34
GNOG.LGlobal X Genomics & Biotechnology UCITS ETF2.19
GNOM.LGlobal X Genomics & Biotechnology UCITS ETF2.12
WBIO.LWisdomTree BioRevolution UCITS ETF USD Acc1.89
BIGT.LL&G Pharma Breakthrough UCITS ETF1.74
DOCG.LL&G Healthcare Breakthrough UCITS ETF1.73
HEAW.LSPDR MSCI World Health Care UCITS ETF1.17

S&P 500 Index

How to choose period

Historical Sharpe Ratio

The chart shows HEAW.L's rolling Sharpe ratio over time compared to your chosen benchmark. Rising trends indicate improving returns relative to total volatility, while declining trends may signal deteriorating risk-adjusted performance or increased volatility. Use multiple timeframes to distinguish short-term fluctuations from long-term patterns.

Identify market cycles by observing when HEAW.L consistently outperforms (line above benchmark), underperforms (below benchmark), or aligns with the benchmark.


Loading charts...

Sharpe Ratio Calculator

How does HEAW.L fit in your portfolio?

Add your other holdings to see your portfolio's Sharpe Ratio and find out.

Analyze Your Portfolio